

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

18 Sep 2026

### Effect of *Salvia officinalis* Tablet on lipid profile and quality of life in postmenopausal women

#### Protocol summary

##### Study aim

The effect of sage on serum lipids and quality of life in postmenopausal women

##### Design

Clinical trial with control group, with parallel groups, double-blind, randomized by permutation method

##### Settings and conduct

The researcher-made demographic information questionnaire and the quality of life questionnaire of postmenopausal women are completed by the researcher. The samples are controlled for serum lipids, including cholesterol, triglycerides, LDL and HDL. They are then intervened with medication or placebo for 8 weeks. The intervention is in the form of oral tablets of 100 mg of sage extract or placebo three times a day. At the end of 8 weeks, the questionnaire of quality of life of postmenopausal women is completed again by the researcher and the tests are repeated, and the results are compared and statistically analyzed. Will be located. The study site is health centers in Shiraz.

##### Participants/Inclusion and exclusion criteria

Inclusion criteria: Menopausal women between the ages of 45-60, without any serious physical or mental illness, without any use of hormonal drugs, with body mass index less than 29, no smoking, no allergies. Exclusion criteria: use of hormonal drugs, beta-blocker, thiazide, allergy, use of any drug that affects menopause, blood lipid level more than 300mg

##### Intervention groups

After obtaining informed consent and providing the necessary explanations, 100 mg oral sage extract tablets were prescribed daily for the intervention group and placebo for the control group.

##### Main outcome variables

Quality of life, serum lipids

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20140622018187N12**

Registration date: **2020-08-17, 1399/05/27**

Registration timing: **retrospective**

Last update: **2020-08-17, 1399/05/27**

Update count: **0**

##### Registration date

2020-08-17, 1399/05/27

##### Registrant information

##### Name

Sedighe Forouhari

##### Name of organization / entity

Shiraz University of Medical Sciences

##### Country

Iran (Islamic Republic of)

##### Phone

+98 987136474257

##### Email address

foruharis@sums.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

Vice chancellor for research Shiraz University of Medical Sciences

##### Expected recruitment start date

2014-05-22, 1393/03/01

##### Expected recruitment end date

2014-06-22, 1393/04/01

##### Actual recruitment start date

2014-05-22, 1393/03/01

##### Actual recruitment end date

2014-06-22, 1393/04/01

##### Trial completion date

2014-06-22, 1393/04/01

##### Scientific title

|                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|--------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Effect of Salvia officinalis Tablet on lipid profile and quality of life in postmenopausal women |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Public title</b>                                                                              | The effect of Salvia officinalis on lipid profile and quality of life in postmenopausal women                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Purpose</b>                                                                                   | Treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Inclusion/Exclusion criteria</b>                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Inclusion criteria:</b>                                                                       | Age between 45 and 60 years Menstruation in the past year Conscious written consent No known physical or mental illness Do not take any hormonal medications to reduce menopausal symptoms in the past month Do not take lipid-lowering drugs BMI below 29 No history of allergy to herbal medicines No smoking, hookah or drug addiction                                                                                                                                                        |
| <b>Exclusion criteria:</b>                                                                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Age</b>                                                                                       | From <b>45 years</b> old to <b>60 years</b> old                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Gender</b>                                                                                    | Female                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Phase</b>                                                                                     | 2-3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Groups that have been masked</b>                                                              | <ul style="list-style-type: none"> <li>Participant</li> <li>Care provider</li> <li>Investigator</li> <li>Outcome assessor</li> </ul>                                                                                                                                                                                                                                                                                                                                                             |
| <b>Sample size</b>                                                                               | Target sample size: <b>102</b><br>Actual sample size reached: <b>100</b>                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Randomization (investigator's opinion)</b>                                                    | Randomized                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Randomization description</b>                                                                 | The population of eligible women is randomly assigned to two groups using a random permutation block design. The groups are placed and if the numbers 5 to 9 are observed, two people are placed in two groups as BA permutations and we repeat this until we have 51 people in each group. Thus, the samples are divided into two groups A (drug group A) and group B (group consuming drug B) are divided. Women are also informed that they will be accidentally placed in one of the groups. |
| <b>Blinding (investigator's opinion)</b>                                                         | Double blinded                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Blinding description</b>                                                                      | This study is a double-blind study and the patient and the researcher are not aware of receiving sage and placebo, and both are prepared by the Faculty of Pharmacy and will be provided to the patient with a code. After completing the research, the type of intervention will be determined with codes.                                                                                                                                                                                      |
| <b>Placebo</b>                                                                                   | Used                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Assignment</b>                                                                                | Parallel                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Other design features</b>                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

## Secondary Ids

empty

## Ethics committees

### 1

#### Ethics committee

##### Name of ethics committee

Ethics Committee, Shiraz University of Medical Sciences

##### Street address

Research Deputy, Shiraz University of Medical Science shiraz

##### City

Shiraz

##### Province

Fars

##### Postal code

1978-71345

#### Approval date

2014-03-19, 1392/12/28

#### Ethics committee reference number

93-01-50-7632

## Health conditions studied

### 1

#### Description of health condition studied

Menopausal and femal climacteric state

#### ICD-10 code

N95.1

#### ICD-10 code description

Menopausal and other perimenopausal disorders

## Primary outcomes

### 1

#### Description

cholesterol

#### Timepoint

1 week before the intervention and 8 weeks after intervention

#### Method of measurement

Laboratory

### 2

#### Description

Triglycerides

#### Timepoint

1 week before the intervention and 8 weeks after intervention

#### Method of measurement

Laboratory

### 3

#### Description

HDL  
**Timepoint**  
1 week before the intervention and 8 weeks after intervention  
**Method of measurement**  
Laboratory

#### 4

**Description**  
LDL  
**Timepoint**  
1 week before the intervention and 8 weeks after intervention  
**Method of measurement**  
Laboratory

### Secondary outcomes

#### 1

**Description**  
Menopause Quality Of Life  
**Timepoint**  
1 week before the intervention and 8 weeks after intervention  
**Method of measurement**  
Menopause Quality Of Life Questionnaire

### Intervention groups

#### 1

**Description**  
Salvia officinalis extract, 100 mg tablet, three times daily for 8 weeks.  
**Category**  
Treatment - Drugs

#### 2

**Description**  
Placebo, tablets 100 mg, three times daily, 8 weeks.  
**Category**  
Placebo

### Recruitment centers

#### 1

**Recruitment center**  
**Name of recruitment center**  
Shahid Motahari Clinic in Shiraz, Namazi Square, Shiraz  
**Full name of responsible person**  
Sedighe Foruhari  
**Street address**  
College Of Nursing Midwifery, Shiraz  
**City**  
Shiraz  
**Province**  
Fars

**Postal code**  
71345-1978  
**Phone**  
+98 71 1647 4257  
**Email**  
forouharism@yahoo.com

### Sponsors / Funding sources

#### 1

**Sponsor**  
**Name of organization / entity**  
Shiraz University of Medical Sciences  
**Full name of responsible person**  
Dr Seyed Basir Hashemi  
**Street address**  
Technology and Research Office, Research Deputy , Shiraz University of Medical Science, Zand Street, Shiraz  
**City**  
Shiraz  
**Province**  
Fars  
**Postal code**  
71348-14336  
**Phone**  
+98 71 3230 5410  
**Email**  
president@sums.ac.ir  
**Grant name**  
**Grant code / Reference number**  
**Is the source of funding the same sponsor organization/entity?**  
Yes  
**Title of funding source**  
Shiraz University of Medical Sciences  
**Proportion provided by this source**  
100  
**Public or private sector**  
Public  
**Domestic or foreign origin**  
Domestic  
**Category of foreign source of funding**  
empty  
**Country of origin**  
**Type of organization providing the funding**  
Academic

### Person responsible for general inquiries

**Contact**  
**Name of organization / entity**  
Shiraz University of Medical Sciences  
**Full name of responsible person**  
Sedighe Foruhari  
**Position**  
Ph.D , Supervisor  
**Latest degree**  
Ph.D.  
**Other areas of specialty/work**  
Gynecology and Obstetrics

**Street address**

College Of Nursing Midwifery, Shiraz

**City**

Shiraz

**Province**

Fars

**Postal code**

71345-1978

**Phone**

+98 71 3647 4257

**Fax****Email**

forouharism@yahoo.com

**Web page address**

## Person responsible for scientific inquiries

**Contact****Name of organization / entity**

Shiraz University of Medical Sciences

**Full name of responsible person**

Sedighe Forouhari

**Position**

Ph.D , Supervisor

**Latest degree**

Ph.D.

**Other areas of specialty/work**

Gynecology and Obstetrics

**Street address**

College Of Nursing Midwifery, Shiraz

**City**

Shiraz

**Province**

Fars

**Postal code**

71345-1978

**Phone**

+98 71 3647 4257

**Fax****Email**

foruharis@sums.ac

**Web page address**

## Person responsible for updating data

**Contact****Name of organization / entity**

Shiraz University of Medical Sciences

**Full name of responsible person**

Sedighe Forouhari

**Position**

Ph.D , Supervisor

**Latest degree**

Ph.D.

**Other areas of specialty/work**

Gynecology and Obstetrics

**Street address**

College Of Nursing Midwifery, Shiraz

**City**

Shiraz

**Province**

Fars

**Postal code**

71345-1978

**Phone**

+98 71 1647 4257

**Fax****Email**

forouharism@yahoo.com

**Web page address**

## Sharing plan

**Deidentified Individual Participant Data Set (IPD)**

Undecided - It is not yet known if there will be a plan to make this available

**Study Protocol**

Undecided - It is not yet known if there will be a plan to make this available

**Statistical Analysis Plan**

Undecided - It is not yet known if there will be a plan to make this available

**Informed Consent Form**

Undecided - It is not yet known if there will be a plan to make this available

**Clinical Study Report**

Undecided - It is not yet known if there will be a plan to make this available

**Analytic Code**

Undecided - It is not yet known if there will be a plan to make this available

**Data Dictionary**

Undecided - It is not yet known if there will be a plan to make this available